EPI-589   Click here for help

GtoPdb Ligand ID: 13272

Synonyms: EPI589
Compound class: Synthetic organic
Comment: EPI-589 is a free-radical scavenger that was proposed to reduce cellular oxidative stress and mitochondrial dysfunction. The reduced form of EPI-589 is a substrate of NAD(P)H quinone oxidoreductases. EPI-589 is blood-brain barrier permeable and orally bioavailable.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 97.46
Molecular weight 265.31
XLogP -1.16
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=C(C)C(=O)C(=C(C)C1=O)CC[C@](C)(C(=O)N)O
Isomeric SMILES CC1=C(C(=O)C(=C(C1=O)C)CC[C@](C)(C(=O)N)O)C
InChI InChI=1S/C14H19NO4/c1-7-8(2)12(17)10(9(3)11(7)16)5-6-14(4,19)13(15)18/h19H,5-6H2,1-4H3,(H2,15,18)/t14-/m1/s1
InChI Key BAANPNDZFYBQIB-CQSZACIVSA-N
No information available.
Summary of Clinical Use Click here for help
EPI-589 is a clinical candidate for neurodegenerative diseases [1-2]. The FDA designated EPI-589 as an orphan drug for ALS in July 2017.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02462603 Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease Phase 2 Interventional Edison Pharmaceuticals Inc
NCT02460679 Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) Phase 2 Interventional PTC Therapeutics